Beatrice Bortesi

Parma, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer.

RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer.

Journal: NPJ breast cancer
Published: July 31, 2025

Phenotypic Expansion of Autosomal Dominant LZTR1-Related Disorders with Special Emphasis on Adult-Onset Features.

Phenotypic Expansion of Autosomal Dominant LZTR1-Related Disorders with Special Emphasis on Adult-Onset Features.

Journal: Genes
Published: May 03, 2024

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents.

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents.

Journal: ESMO open
Published: February 12, 2024

Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing.

Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing.

Journal: Genes
Published: December 30, 2023

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer.

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer.

Journal: Breast (Edinburgh, Scotland)
Published: March 21, 2022

Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers.

Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers.

Journal: Frontiers in oncology
Published: April 27, 2021

Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

Journal: ESMO open
Published: October 25, 2020

Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review.

Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review.

Journal: Frontiers in oncology
Published: April 27, 2019

Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.

Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.

Journal: Human mutation
Published: January 30, 2019

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 30, 2017

Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.

Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.

Journal: Acta bio-medica : Atenei Parmensis
Published: September 23, 2015

Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder.

Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder.

Journal: Tumori
Published: June 30, 2015
Showing 1-12 of 23

Last Updated: 09/26/2026